Solocalm

Solocalm - General Information

A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. [PubChem]

Pharmacology of Solocalm

Solocalm is in a class of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). Solocalm works by reducing hormones that cause inflammation and pain in the body. Solocalm is used to reduce the pain, inflammation, and stiffness caused by rheumatoid arthritis and osteoarthritis.

Solocalm for patients

FELDENE, like other drugs of its class, is not free of side effects. The side effects of these drugs can cause discomfort and rarely, there are more serious side effects, such as gastrointestinal bleeding, which may result in hospitalization and even fatal outcomes.

NSAIDs (Nonsteroidal Anti-Inflammatory Drugs) are often essential agents in the management of arthritis, but they also may be commonly employed for conditions which are less serious.

Physicians may w.s. to discuss with their patients the potential risks and likely benefits of NSAID treatment, particularly when the drugs are used for less serious conditions where treatment without NSAIDs may represent an acceptable alternative to both the patient and physician.

Solocalm Interactions

FELDENE is highly protein bound, and therefore, might be expected to displace other protein-bound drugs. Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs.

Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels.

Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. It is recommended that plasma lithium levels be monitored when initiating, adjusting and discontinuing FELDENE.

Solocalm Contraindications

FELDENE should not be used in patients who have previously exhibited hypersensitivity to it, or in individuals with the syndrome comprised of bronchospasm, nasal polyps, and angioedema precipitated by aspirin or other nonsteroidal anti-inflammatory drugs.

Additional information about Solocalm

Solocalm Indication: For treatment of osteoarthritis and rheumatoid arthritis.
Mechanism Of Action: The antiinflammatory effect of Solocalm may result from the reversible inhibition of cyclooxygenase, causing the peripheral inhibition of prostaglandin synthesis. The prostaglandins are produced by an enzyme called Cox-1. Solocalm blocks the Cox-1 enzyme, resulting into the disruption of production of prostaglandins. Solocalm also inhibits the migration of leukocytes into sites of inflammation and prevents the formation of thromboxane A2, an aggregating agent, by the platelets.
Drug Interactions: Acebutolol Risk of inhibition of renal prostaglandins
Atenolol Risk of inhibition of renal prostaglandins
Betaxolol Risk of inhibition of renal prostaglandins
Bevantolol Risk of inhibition of renal prostaglandins
Bisoprolol Risk of inhibition of renal prostaglandins
Carteolol Risk of inhibition of renal prostaglandins
Carvedilol Risk of inhibition of renal prostaglandins
Esmolol Risk of inhibition of renal prostaglandins
Labetalol Risk of inhibition of renal prostaglandins
Metoprolol Risk of inhibition of renal prostaglandins
Nadolol Risk of inhibition of renal prostaglandins
Oxprenolol Risk of inhibition of renal prostaglandins
Penbutolol Risk of inhibition of renal prostaglandins
Pindolol Risk of inhibition of renal prostaglandins
Practolol Risk of inhibition of renal prostaglandins
Propranolol Risk of inhibition of renal prostaglandins
Sotalol Risk of inhibition of renal prostaglandins
Timolol Risk of inhibition of renal prostaglandins
Ritonavir Ritonavir increases the toxicity of piroxicam
Warfarin The NSAID increases the anticoagulant effect
Acenocoumarol The NSAID increases the anticoagulant effect
Dicumarol The NSAID increases the anticoagulant effect
Anisindione The NSAID increases the anticoagulant effect
Lithium The NSAID increases serum levels of lithium
Methotrexate The NSAID increases the effect and toxicity of methotrexate
Cyclosporine Monitor for nephrotoxicity
Alendronate Increased risk of gastric toxicity
Food Interactions: Not Available
Generic Name: Piroxicam
Synonyms: Not Available
Drug Category: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors
Drug Type: Small Molecule; Approved

Other Brand Names containing Piroxicam: Apo-Piroxicam; Artroxicam; Baxo; Bruxicam; Caliment; Erazon; Feldene; Flogobene; Geldene; Improntal; Larapam; Pipoxicam; Pirkam; Piroflex; Reudene; Riacen; Roxicam; Roxiden; Sasulen; Solocalm; Zunden; piroxicam usp;
Absorption: Well absorbed following oral administration.
Toxicity (Overdose): Symptoms of overdose include drowsiness, nausea, stomach pain, and/or vomiting.
Protein Binding: Not Available
Biotransformation: Renal
Half Life: 30 to 86 hours
Dosage Forms of Solocalm: Tablet Oral
Suppository Rectal
Capsule Oral
Chemical IUPAC Name: (3E)-3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxobenzo[e]thiazin-4-one
Chemical Formula: C15H13N3O4S
Piroxicam on Wikipedia: https://en.wikipedia.org/wiki/Piroxicam
Organisms Affected: Humans and other mammals